Price$28.46-0.13 (-0.44%)
01:30 PM06:15 PM
News · 26 weeks56-27%
2025-12-072026-05-31
Mix3590d
- Insider16(46%)
- SEC Filings8(23%)
- Other6(17%)
- Earnings3(9%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $261,266 worth of shares (9,219 units at $28.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Heartflow, Inc. (0001464521) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.SCHEDULE 13G/A - Heartflow, Inc. (0001464521) (Subject)
- SECSEC Form 10-Q filed by Heartflow Inc.10-Q - Heartflow, Inc. (0001464521) (Filer)
- SECHeartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Heartflow, Inc. (0001464521) (Filer)
- PRHeartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 GuidanceSAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41% increase year-over-yearGross margin of 80.2%, non-GAAP gross margin of 80.5%Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million 2026 Annual Guidance Total revenue of $228 million to $232 million (approximately 29% to 32% growt
- INSIDERChief Executive Officer Farquhar John C.M. sold $657,005 worth of shares (22,562 units at $29.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 519,397 units (SEC Form 4)4 - Heartflow, Inc. (0001464521) (Issuer)
- PRA Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in MedtechVMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
- PRThe Future of Intoxication Detection May Be in Your VoiceAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming
- INSIDERChief Accounting Officer Jones Marie L. covered exercise/tax liability with 567 units of Common Stock., decreasing direct ownership by 2% to 31,083 units (SEC Form 4) (withholding tax)4 - Heartflow, Inc. (0001464521) (Issuer)
- INSIDERChief Medical Officer Rogers Campbell covered exercise/tax liability with 2,271 shares, decreasing direct ownership by 3% to 78,731 units (SEC Form 4) (withholding obligation)4 - Heartflow, Inc. (0001464521) (Issuer)
- INSIDERChief Financial Officer Verghese Vikram covered exercise/tax liability with 2,009 units of Common Stock., decreasing direct ownership by 0.94% to 210,854 units (SEC Form 4) to cover taxes4 - Heartflow, Inc. (0001464521) (Issuer)
- INSIDERChief Executive Officer Farquhar John C.M. covered exercise/tax liability with 7,204 shares, decreasing direct ownership by 1% to 541,959 units (SEC Form 4) to cover withholding tax4 - Heartflow, Inc. (0001464521) (Issuer)
- ANALYSTWilliam Blair initiated coverage on HeartflowWilliam Blair initiated coverage of Heartflow with a rating of Outperform
- INSIDERLarge owner Bain Capital Life Sciences Investors, Llc sold $58,898,336 worth of shares (2,000,000 units at $29.45) (SEC Form 4)4 - Heartflow, Inc. (0001464521) (Issuer)
- SECSEC Form DEFA14A filed by Heartflow Inc.DEFA14A - Heartflow, Inc. (0001464521) (Filer)
- SECSEC Form DEF 14A filed by Heartflow Inc.DEF 14A - Heartflow, Inc. (0001464521) (Filer)
- PRHeartflow to Report First Quarter 2026 Financial Results on May 14, 2026SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live an
- INSIDERSEC Form 4 filed by Farquhar John C.M.4 - Heartflow, Inc. (0001464521) (Issuer)
- PRHeartflow Files Patent Infringement Lawsuit Against CleerlyMOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed a patent infringement lawsuit against Cleerly, Inc. in the United States District Court for the Eastern District of Texas. The complaint seeks permanent injunctive relief and damages arising from Cleerly's unauthorized and continued use of Heartflow's patented technology. Heartflow asserts that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six of Heartflow's patents with priority dates from 2012 to 2018, protecting Heartflow innovations developed years before the introductio
- INSIDERSEC Form 4 filed by Rogers Campbell4 - Heartflow, Inc. (0001464521) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Heartflow Inc.SCHEDULE 13G - Heartflow, Inc. (0001464521) (Subject)
- PRHow Decentralized AI is Unlocking Value in Cardiac DiagnosticsISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit
- INSIDERSEC Form 4 filed by Lightcap Jeffrey C4 - Heartflow, Inc. (0001464521) (Issuer)
- INSIDERSEC Form 4 filed by Healthcor Partners Management Lp4 - Heartflow, Inc. (0001464521) (Issuer)
- INSIDERSEC Form 4 filed by Rogers Campbell4 - Heartflow, Inc. (0001464521) (Issuer)
HTFL FAQ
6 questionsWhere does HTFL stock trade?
Heartflow Inc. (HTFL) is listed on NASDAQ.What sector and industry is HTFL in?
Heartflow Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Heartflow Inc. go public?
Heartflow Inc. (HTFL) completed its IPO in 2025.What are analysts saying about HTFL?
Heartflow Inc. has had 7 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-05-04. Recent price targets range from $3500.00 to $3800.00.What companies are similar to HTFL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare HTFL side-by-side with any of them on Quantisnow.How can I track HTFL on Quantisnow?
Quantisnow aggregates Heartflow Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HTFL to receive live email and push alerts on every new disclosure.